Cancer Immunotherapy in the Modern Era. David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee
|
|
- Maximilian Tate
- 5 years ago
- Views:
Transcription
1 Cancer Immunotherapy in the Modern Era David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee
2 Key Events in the History of Cancer Immunotherapy 1890 First cancer vaccine developed (Coley) 1960s Adjuvants (eg, BCG) shown to eradicate some tumors 1986 IFN-α approved as cancer immunotherapy 1991 First tumor-associated antigen cloned (MAGE-1) Dendritic Cell Vaccines 1953 Coley s work first published 1985 Adoptive immunotherapy for patients with cancer 1992 IL-2 approved as cancer immunotherapy Immune Checkpoint Inhibitors
3
4 Selected Cells of the Human Immune System Dendritic cell (DC) A variety of cells can capture and process antigens and present antigens to T cells in context of self-mhc (dendritic cells, macrophages, B cells) Dendritic cells are primary or professional antigen presenting cells Helper T cell Recognizes antigens and produces cytokines that activate a T-cell or B-cell response (adaptive response) Cytotoxic and regulatory T lymphocytes (CTL and Tregs) Following sensitization, attacks and lyses cells bearing target antigen (adaptive response); suppression of immune response MHC, major histocompatibility complex. Armstrong AC, et al. BMJ. 2001;323(7324):
5 Fundamentals of the Cellular Anticancer Immune Response Tumor Step 4: Lymphocytes kill tumor cells Tumor cells Step 1: Antigen processing CTL DC Step 3: Lymphocyte activation T-cell receptor Antigen- MHC DC Step 2: Antigen presentation T cell Lymph nodes and spleen
6 A Roadmap of Immunotherapy-Tumor Interactions 4 Trafficking of T cells to tumors Priming and activation Anti-CTLA4 Anti-CD137 (agonist) Anti-OX40 (agonist) Anti-CD27 (agonist) IL-2 IL Infiltration of T cells into tumors Anti-VEGF Cancer antigen presentation Vaccines IFN-α GM-CSF Anti-CD40 (agonist) TLR agonists 2 6 Recognition of cancer cells by T cells CARs Release of cancer cell antigens Chemotherapy Radiation therapy Targeted therapy 1 7 Killing of cancer cells Anti-PD-L1 Anti-PD-1 IDO inhibitors Chen DS, et al. Immunity. 2013;39(1):1-10.
7 Immunotherapy Approaches Immunotherapy Specific: Requires defined antigen source Specific: T-cell targeted Non-specific: Host must define antigen Adoptive: response generated ex vivo Active: requires host immunocompetence PD-1/PD-L1 CTLA-4 Cytokines Other ACT Vaccines IFN IL-2 Bavituximab Toll-like receptor agonists Talactoferrin
8 Cancer Vaccines: Proposed Mechanism of Action Intradermal Vaccine: Protein or Peptide + Adjuvant Adjuvant Activates DC Target Peptides Class II MHC Specific CD4 T cell TCR Class I MHC Antigen Uptake by Immature DC TCR CD8 T cell Drake CG, et al. Nat Rev Clin Oncol. 2014;11(1): ACTIVATED CD8 T cell
9 Phase III IMPACT Study: Sipuleucel-T in mcrpc Sipuleucel-T: cellular immunotherapy produced by exposing a patient s leukapheresed cells to recombinant fusion protein consisting of prostatic acid phosphatase antigen and GM-CSF Patients with asymptomatic or minimally symptomatic mcrpc (N = 512) Randomized 2:1* Primary endpoint: OS Sipuleucel-T q2w x 3 (n = 341) Placebo q2w x 3 (n = 171) Kantoff P, et al. New Engl J Med. 2010;363(5): Treat at physician discretion Treat at physician discretion and/or salvage protocol *Stratified by primary Gleason score, number of bone metastases, and bisphosphonate use P R O G R E S S I O N
10 Sipuleucel-T Immunotherapy in mcrpc: IMPACT Probability of Survival, % Placebo (n = 171) Median Survival: 21.7 Mos. Kantoff P, et al. New Engl J Med. 2010;363(5): Median OS benefit: 4.1 months HR : 0.78 (95% CI: ; P =.03) Sipuleucel-T (n = 341) Median Survival: 25.8 Mos Months Since Randomization
11 Selected Vaccine Trials in Patients With NSCLC Vaccine N TNM Stage Whole-Cell Vaccines Belagenpumatucel-L 1 75 II-IV Antigen-Specific Vaccines CIMAvax-EGF* 2 83 IIIB-IV MAGE-A IB-II L-BLP IIIB-IV TG III/IV Efficacy Outcomes Improved survival in patients treated with higher doses; 15% RR in advanced stages 5 mos improvement in survival in patients with seroconversion (8.4 mos vs 3.5 mos) Trend toward improvement of disease-free interval in MAGE-A3 treated group Stage IIIB patients: median OS NR vs 13.3 mos (2-yr survival rate: 60.0% vs 36.7%) Patients with activated NK phenotype had higher median OS when treated with vaccine plus chemotherapy vs chemotherapy alone (18 mos vs 11.3 mos) *Pooled analysis from 3 trials 1. Nemunaitis J, et al. J Clin Oncol. 2006;24(29): Gonzalez G, et al. Hum Vaccin. 2007;3(1): Vansteenkiste J, et al. J Clin Oncol. 2007;25(18S):Abstract Butts C, et al. J Clin Oncol. 2005;23(27): Acres B, et al. J Clin Oncol. 2009;27(15S): Abstract 3027.
12 Cancer Vaccines: Issues Induce immune reaction against vaccine, but not the tumor Immune system mainly recognizes neo-antigens from passenger mutations rather than shared antigens Antigens different for each tumor Vaccine must involve autologous tumor cells Most immune-responsive tumors autovaccinate, but immune regulation prevents an effective response Even if vaccine enhances antitumor immunity, cells likely to be suppressed in the tumor microenvironment Conclusion: Vaccines are unlikely to have a major effect in the absence of immune checkpoint control
13 Ipilimumab: Mechanism of Action T-cell activation T-cell inhibition T-cell potentiation T-cell CTLA-4 T-cell T-cell TCR CD28 TCR CD28 CTLA-4 TCR CTLA-4 APC MHC B7 APC MHC B7 APC MHC B7 IPILIMUMAB blocks CTLA-4 Hodi FS, et al. N Engl J Med. 2010;363(8):
14 Ipilimumab in Metastatic Melanoma Previously Treated Patients Previously Untreated Patients OS, % Median OS, Mos Ipi + gp Ipi 10.1 gp HR P Value < Months Patients Survival, % Ipi + D Placebo + D Median OS, Mos Est 1, 2, 3-Yr Survival, % 47.3, 28.5, , 17.9, 12.2 HR 0.72 P Value <.001 Ipilimumab + dacarbazine Placebo + dacarbazine Months Ipilimumab + gp100 vs gp100 1 Ipilimumab vs Placebo 2 1. Hodi FS, et al. N Engl J Med. 2010;363(8): Robert C, et al. N Engl J Med. 2011;364(26):
15 Response Criteria for Immunotherapy RECIST CR PR SD PD Disappearance of all target lesions, reduction in shortaxis diameter of pathology LN to <10 mm 30% decrease in sum of longest diameters of target lesions Neither PR nor PD Immune-Related Response Criteria 2 20% increase ( 5 mm absolute increase) in sum of longest diameters, in comparison with smallest sum of longest diameters recorded during treatment ircr irpr irsd irpd Disappearance of all lesions on 2 consecutive observations 4 weeks apart 50% decrease in tumor burden compared with baseline in 2 observations 4 weeks apart 50% decrease in tumor burden compared with baseline not established, nor 25% increase vs nadir 25% increase in tumor burden compared with nadir (at any single timepoint) in 2 consecutive observations 4 weeks apart 1. Eisenhauer EA, et al. Eur J Cancer. 2009;45(2): Wolchok JD, et al. Clin Cancer Res. 2009;15(23):
16 Association of Response With Survival Proportion Alive CR/PR/SD (by WHO criteria) irpr/irsd (by the irrc) PD and unknown response Months Wolchok JD, et al. Clin Cancer Res. 2009;15(23):
17 Adverse Events Associated With Ipilimumab Are Immune-Related irae (All Grades) 1. Robert C, et al. N Engl J Med. 2011;364(26): Hodi FS, et al. N Engl J Med. 2010;363(8): IPI + DTIC 1 N = 247 IPI + PBO 2 N = 251 Total, % Dermatologic, % Pruritus Rash Gastrointestinal, % Diarrhea Colitis Hepatic, % Increase in alanine aminotransferase Increase in aspartate aminotransferase Hepatitis Rate of grade 3/4 toxicity, % irae, immune-related adverse event
18 Identification of Immune-Related AEs iraes associated with ipilimumab are well known Patients receiving ipilimumab therapy should be monitored for early identification of these iraes Organ System Gastrointestinal Signs/Symptoms Any change in normal bowel habits or change from baseline Liver Skin Neurologic Endocrine Elevation in liver function tests AST >2.5 x ULN ALT >2.5 x ULN Total bilirubin >1.5 x ULN Pruritus, rash Motor and sensory neuropathy Unilateral and bilateral weakness Sensory alterations Paresthesia Fatigue, headache, changes in mental status, abdominal pain, unusual bowel habits, hypotension, abnormal thyroid function tests and/or serum chemistry values Ipilimumab Immune-Mediated Adverse Reaction Management Guide. Available at: Accessed October 16, 2014.
19 General Principles of Immune-Related Toxicity Management Generally based on severity of symptoms Grade 1: supportive care; +/- withhold drug Grade 2: withhold drug, consider redose if toxicity resolves to grade 1. Low-dose corticosteroids (prednisone 0.5 mg/kg/day or equivalent) if symptoms do not resolve within a week Grade 3-4: discontinue drug; high-dose corticosteroids (prednisone 1-2 mg/kg/day or equivalent) tapered over 1 month once toxicity resolves to grade 1 Presence of iraes may be a biomarker for response
20 Less Common Immune-Related Adverse Events Hematologic (hemolytic anemia, thrombocytopenia) Cardiovascular (myocarditis, pericarditis, vasculitis) Ocular (blepharitis, conjunctivitis, iritis, scleritis, uveitis) Renal (nephritis)
21 Selection of Patients Predictive biomarkers Clinical features associated with response or resistance Tumor burden and rate of disease progression Kinetics of tumor response for immune therapy versus alternate therapies Clinical contraindications (autoimmunity, drug interactions) Potential for durable response with immune therapy versus alternate therapies (requirement for ongoing treatment) Availability and toxicity/effectiveness of alternate therapies
22 The Next Generation of Cancer Immunotherapy David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee
23 Programmed Death Receptor (PD-1) PD-1 is expressed on T, B, and NK cells Ligands are PD-L1 and -L2, expressed on APCs and tumor cells Ligation inhibits T-cell activation and proliferation causing cell-cycle arrest without apoptosis More subtle immune checkpoint than CTLA-4 mabs against PD-1 and PDL-1 results in tumor regression Clonal exhaustion in infectious diseases; these clones express high levels of PD-1
24 CTLA-4 vs PD-1: Distinct Immune Checkpoints B7.1/2 CD28 APC Signal 1 CTLA-4 to cell surface APC Signal 1 Naïve/resting T cell CTLA-4 Costim. ligand Costim. receptor Experienced T cell APC Traffic to Tissue Signal 1 periphery Signal 1 T-cell priming Topalian SL, et al. Curr Opin Immunol. 2012;24(2): Inflammation PD-L1 PD-1
25 Potential Differences in PD-1 vs PD-L1 Blockade B7.1 APC/target cell? apoptotic signal in tumor cells B7-H1 PD-1 T cell (-) Signal B7-DC Anti PD-1 APC/target cell? apoptotic signal in tumor cells Anti B7-H1 B7-H1 B7.1 PD-1 T cell (-) Signal B7-DC Topalian SL, et al. Curr Opin Immunol. 2012;24(2):
26 PD-1/PD-L1 Inhibitors Currently in Clinical Development Target Agent Class K D Nivolumab IgG4 fully human Ab 3 nm (MDX1106, BMS936558) PD-1 Pembrolizumab (MK-3475) IgG4 engineered humanized Ab 29 pm Pidilizumab (CT-011) IgG1 humanized Ab - AMP-224 Fc-PD-L2 fusion protein - BMS (MDX-1105) IgG4 fully human Ab - PD-L1 MPDL3280A MEDI4736 IgG1 engineered fully human Ab IgG1 engineered fully human Ab - - MSB C NA -
27 Activity of Anti-PD-1 Agents in Solid Tumors Nivolumab Activity (ORR) 1 Melanoma: 28% NSCLC: 18% RCC: 27% Patient with metastatic melanoma Pembrolizumab Activity (ORR) 2 Melanoma: 38% Highest dose: 52% (assessed by RECIST 1.1 with confirmation by ICR) 81% of pts with response still on treatment at time of analysis (median followup: 11 mos) 1. Topalian SL, et al. N Engl J Med. 2012;366(26): Hamid O, et al. N Engl J Med. 2013;369(2):
28 Agent Nivolumab 1 (Anti-PD1) Activity of Anti-PD-1 and Anti-PD-L1 in Metastatic Melanoma Dose and schedule mg/kg q2w N ORR % Median response duration, months Median PFS/ 24-week PFS rate % months Median survival 16.8 months 1 yr/2 yr survival 62%/43% Pembrolizumab 2 (Anti-PD1) 2-10 mg/kg q2-3w 411 (168 IPI-N) 34% (40% IPI-N) NR 5.5 months NR 69%/ND MPDL3280 (Anti- PD-L1) BMS (Anti- PD-L1) mg/kg q3w mg/kg q2w 44 29% ND 43% ND ND 52 17% ND 42% ND ND 1. Topalian SL, et al. J Clin Oncol. 2014;32(10): Ribas A et al. J Clin Oncol. 2014;32(5S): LBA Herbst RS, et al. J Clin Oncol. 2013;31(Suppl): Abstract Brahmer JR, et al. N Engl J Med. 2012;366(26):
29 Outcomes With Nivolumab in Patients With Metastatic RCC Dose, mg/kg Objective Response Rate, % (n/n) Median DoR, Wks (Range) All doses 29.4 (10/34) 56.1 ( ) (5/18) 56.1 ( ) (5/16) 56.1 ( ) 24 Wks SD Rate, % (n/n) 48 Wks 26.5 (9/34) 5.9 (2/34) 22.2 (4/18) 5.6 (1/18) 31.3 (5/16) 6.3 (1/16) Drake CG, et al. J Clin Oncol. 2013;31(Suppl): Abstract 4514.
30 OS: Nivolumab in Patients With Advanced NSCLC Overall Survival OS Rate % (95% CI) [patients at risk] Group Died/Treated Median OS (95% CI) 1-Year 2-Year Censored 1 mg/kg 26/ (5.3, 11.1) 32 (16, 49) [8] 12 (3, 27) [2] 3 mg/kg 20/ (7.3, --) 56 (38, 71) [17] 45 (27, 61) [9] 10 mg/kg 48/ (5.2, 12.4) 40 (27, 52) [23] 19 (10, 31) [9] 1-year OS Rate 56% (17 patients at risk) 2-year OS Rate 45% (9 patients at risk) Months Since Treatment Initiation Patients at Risk Nivolumab 1 mg/kg Nivolumab 3 mg/kg Nivolumab 10 mg/kg Brahmer JR, et al. J Clin Oncol. 2014;32(5s): Abstract 8112.
31 Efficacy of Nivolumab in Untreated Patients With NSCLC Tumor Responses Squamous n = 9 Nonsquamous n = 11 Total n = 20 ORR, n (%) 2 (22) 4 (36) 6 (30) Ongoing responders, n (%) 1 (50) 3 (75) 4 (67) Best overall response, n (%) Complete response 1 (11) 1 (9) 2 (10) Partial response 1 (11) 3 (27) 4 (20) Stable disease 3 (33) 4 (36) 7 (35) Survival Outcomes PFS/OS PFS rate at 24 weeks, % Median PFS, weeks year OS rate, % Gettinger S, et al. J Clin Oncol. 2014;32(5s): Abstract 8024.
32 Nivolumab in Squamous Cell NSCLC Checkmate-063 Trial ORR (~11 months minimum follow up) Nivolumab 3 mg/kg 15% Estimated one-year survival rate 41% Median OS 8.2 months Stable disease 26% Disease control rate 41% Ramalingam SS, et al. Presented at: 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology; October 30-November 1, 2014: Chicago, Illinois. Abstract LB2.
33 Efficacy of Pembrolizumab in Untreated Patients With NSCLC RECIST v1.1, Central Review a irrc, Investigator Review ORR b DCR b ORR b DCR b Pembro Dose n n (%) [95% CI] n (%) [95% CI] n n (%) [95% CI] n (%) [95% CI] 2 mg/kg Q3W 6 2 (33%) [4%-78%] 3 (50%) [12%-88%] 6 4 (67%) [22%-96%] 5 (83%) [36%-100%] 10 mg/kg Q3W 20 4 (20%) [6%-44%] 14 (70%) [46%-88%] (46%) [24%-68%] 18 (82%) [60%-95%] 10 mg/kg Q2W 16 5 (31%) [11%-59%] 10 (63%) [35%-85%] 17 7 (41%) [18%-67%] 12 (71%) [44%-90%] Total (26%) [14%-42%] 27 (64%) [48% 78%] (47%) [32%-62%] 35 (78%) [63%-89%] Interim median PFS c : 27.0 weeks (95% CI, ) by RECIST v1.1 per central review 37.0 weeks (95% CI, 27.0-NR) by irrc per investigator review Analysis cut-off date: March 3, DCR, disease-control rate (complete response + partial response + stable disease) a 3 patients did not have measurable disease by RECIST v1.1 per independent central review at baseline and were not evaluated for response by RECIST v1.1. b Includes confirmed and unconfirmed responses. c From product-limit (Kaplan-Meier) method for censored data. PDL-1 positive at 1% Rizvi NA, et al. J Clin Oncol. 2014;32(5s): Abstract 8007.
34 MEDI4736 (Anti-PD-1) in Patients With NSCLC All patients with 1 follow-up scan (n = 84) Majority of patients have limited follow-up and have not reached week 12 tumor assessment RECIST Response Response evaluable MEDI mg/kg q2w MEDI4736 All doses 13% (6/47) 16% (9/58) PD-L1+ 39% (5/13) 25% (5/20) PD-L1-5% (1/19) 3% (1/29) Disease Control Rate Response Evaluable MEDI mg/kg q2w MEDI4736 All doses 30% (14/17) 35% (20/58) PD-L1+ 54% (7/13) 45% (9/20) PD-L1-32% (6/19) 24% (7/29) Brahmer JR, et al. J Clin Oncol. 2014;32(5s): Abstract 8021.
35 MPDL3280A Phase IA: Efficacy Summary 26 of 29 responders continued to respond at last assessment Time on study in responders: 3 to 15+ months Additional delayed responses not reflected in above ORR Other tumor types (14) include CRC (PR in 1/4) and gastric cancer (PR in 1/1) Population, % Overall population (N = 140) NSCLC (n = 41) Melanoma (n = 38) RCC (n = 47) RECIST 1.1 Response Rate (ORR*) SD of 24 Weeks or Longer 24- Week PFS *ORR includes unconfirmed PR/CR and confirmed PR/CR. Generally well tolerated Grade 3/4 related AE 13%; 2% immune related Herbst RS, et al. J Clin Oncol. 2013;31(Suppl): Abstract 3000.
36 iraes in NSCLC Anti-PD-1 nivolumab (129 NSCLC patients) 53% related AEs, 5% grade 3/4 AEs Pneumonitis 6%, grade 3/4 in 3 patients, 2 deaths Anti-PD-1 pembrolizumab (221 NSCLC patients) 48% related AEs (fatigue), 6% grade 3/4 AEs Pneumonitis grade 3/4 in 3 patients Anti-PD-L1 MPDL3280A (85 NSCLC patients) 66% related AEs, 11% grade 3/4 (fatigue) No grade 3-5 pneumonitis Anti-PD-L1 BMS (207 patients) 61% related AEs, 9% grade 3/4 AEs No pneumonitis Anti-PD-L1 MEDI4736 (26 patients, 13 NSCLC) 34% related AEs, no grade 3/4 AEs, no pneumonitis, no colitis
37 Pneumonitis Grade Grade 1 Radiographic changes only Grade 2 Mild to moderate new symptoms Grade 3-4 Severe new symptoms; new/worsening hypoxia; lifethreatening Management Consider delay of I-O therapy Monitor for symptoms every 2-3 days Consider pulmonary and ID consults Delay I-O therapy Pulmonary and ID consults Monitor symptoms daily, consider hospitalization 1mg/kg/day of prednisolone IV or oral equivalent Consider bronchoscopy, lung biopsy Discontinue I-O therapy Hospitalize Pulmonary and ID consults 2-4 mg/kg/day methylprednisolone IV or IV equivalent Prophylactic antibiotics for opportunistic infections Consider bronchoscopy, lung biopsy Lipson EJ, et al. Presented at the 2014 American Society of Clinical Oncology Annual Meeting - Optimizing the Use of New Targeted Therapies in the Face of Toxicity; May 30-June 3, 2014; Chicago, Illinois.
38 PD-L1 As a Biomarker in NSCLC Nivolumab Pembrolizumab MPDL3280A MEDI4736 Assay C3 SP263 Cells scored Tumor cell membrane Tumor cell (and stroma) Tumor and immune cells Tissue Archival Recent Arch./Recent Arch./Rece nt Setting 1 st line 2L ++ 1 st line 2L ++ 2L ++ 2L ++ Cut-point 5% 1% 5% 1% 1% 50% 1% 5% 10% ORR in PD-L1 + 50% N =10 13% N = 38 15% N = % N = % N = % N = 41 31% N = 26 46% N = 13 83% N = 6 39% N = 13 ORR in PD-L1-0% N = 7 17% N = 30 14% N = 35??? 9-13% N = 40 11% N = 88 20% N =20 18% N = 33 18% N = 40 5% N =19 Topalian SL, et al. N Engl J Med. 2012;366(26): ; Grosso J, et al. J Clin Oncol. 2013;31(Suppl): Abstract 3016; Brahmer JR, et al. J Clin Oncol. 2014;32(5S): Abstract 8112; Gettinger SN, et al. J Clin Oncol. 2014;32(5S): Abstract 8024; Daud AI, et al. Cancer Res. 2014;74(19 Suppl): Abstract CT104; Gandhi L, et al. Cancer Res. 2014;74(19 Suppl): Abstract CT105; Rizvi NA, et al. J Clin Oncol. 2014;32(5S): Abstract 8022; Garon EB, et al. J Clin Oncol. 2014;32(5S): Abstract 8020; Hamid O, et al. J Clin Oncol. 2013;31(Suppl): Abstract 9010; Herbst RS, et al. J Clin Oncol. 2013;31(Suppl): Abstract 3000; Powderly JD, et al. J Clin Oncol. 2013;31(Suppl): Abstract 3001; Spigel DR, et al. J Clin Oncol. 2013;31(Suppl): Abstract 8008; Segal NH, et al. J Clin Oncol. 2014;32(5S): Abstract 3002; BrahmerJR, et al. J Clin Oncol. 2014;32(5S): Abstract 8021.
39 Possible Limitations to PD-L1 PD-L1 expression is dynamic PD-L1 is heterogeneous within tissue Unclear what level of expression is important Importance of co-localization with TILs Scalability and reliability of assays Archived material Variability in tissue collection timing, cell sampling, mab used for staining, IHC criteria
40 PD-1/PD-L1 Therapy: Select Pivotal Trials Tumor Type Melanoma RCC NSCLC Phase III (unless otherwise indicated) Pembro (2 doses) vs ipi [NCT ] Nivo vs ipi vs ipi/nivo [NCT ] Nivo vs chemo (ipi progression) [NCT ,NCT ] Pembro vs chemo (ipi progression; phase II) [NCT ] Nivo vs everolimus (TKI progression) [NCT ] Nivo/ipi vs sunitinib MPDL + bev vs MPDL vs sunitinib (phase II) [NCT ] Pembro (2 doses) vs doc [NCT ] Nivo vs doc (squamous or nonsquamous) [NCT , NCT ] Nivo vs chemo choice [NCT ] HNSCC Nivo vs investigator s choice [NCT ] Patients with known or suspected autoimmune disease are generally excluded from these trials.
41 Many Potential Immunotherapy Combinations Immune-checkpoint blockade is still early in development Future is likely in combinations Multiple checkpoints (eg, PD-1 + LAG3) Small molecule inhibitors (eg, VEGFi or inos modulation + PD-L1) Radiation (eg, CTLA-4 or OX40 + RT) Chemotherapy (eg, cyclophosphamide to deplete T reg prior to checkpoint blockade) Adoptive cell therapy Grosso JF, et al. Cancer Immun. 2013;13:5.
42 Ipilimumab + Nivolumab for Melanoma Change in Target Lesions From Baseline, % First occurrence of new lesion Cohort 2: 1 mg/kg nivolumab + 3 mg/kg ipilimumab Weeks Since Treatment Initiation Change in Target Lesions From Baseline All Patients in Concurrent Cohorts Patients Therapy, % ORR 80% Tumor Reduction Ipilimumab 7 <3 Nivolumab 28 <2 Combination (cohort 2) Wolchok JD, et al. N Engl J Med. 2013;356(2): Wolchok JD, et al. J Clin Oncol. 2013;31(Suppl): Abstract 9012.
43 Phase I Study of Nivolumab + Ipilimumab in mrcc Change in Baseline, % Change in Baseline Target Lesions, % Weeks Since First Dose Hammers HJ, et al. J Clin Oncol. 2014;32(5S): Abstract Weeks Since First Dose N3 + I1 (n = 20) N1 + I3 (n = 22) 1st Occurrence of New Lesion
44 What About Other Combinations? Combinations of immunotherapies with other classes of therapy Targeted therapies Vaccines Metabolites Radiation Chemotherapy
45 Combining Immunotherapy and Targeted Therapy OS (%) Improved Survival With Ipilimumab Immunotherapy Ipi + gp100 Ipi gp Targeted Therapy Combination??? Percent Alive Percent Alive Percent Alive Mos 44 OS (%) Improved Survival With Vemurafenib Vemurafenib (n = 336) 6 mos OS: 84% Dacarbazine (n = 336) 20 6 mo OS: 64% Mos Yrs Yrs Yrs 1. Hodi FS, et al. N Engl J Med. 2010;363(8): Chapman PB, et al. N Eng J Med. 2011; 364(26):
46 Combination Therapy May Result in Increased Toxicity Patient Number Cohort 1* Doses of Ipilimumab Before ALT-AST Elevation, n Time to Onset of ALT-AST Elevation After First Dose Ipilimumab, Days Treatment GCS; Vem discontinued for 5 days then restarted with dose reduction; Ipi permanently discontinued GCS; Vem discontinued for 4 days then restarted with dose reduction; Ipi continued (2 doses) GCS; Vem discontinued for 5 days then restarted with dose reduction; Ipi continued (1 dose) GCS; Vem discontinued for 4 days then restarted with dose reduction; Ipi continued (1 dose) Time to Resolution of ALT-AST Elevation, Days Toxicity Relapse With Repeated Ipilimumab 4 NA 6 No 6 No 12 Yes Cohort GCS; Vem discontinued for 7 days then restarted with dose reduction; Ipi permanently discontinued (1 dose) 10 NA Vem and Ipi permanently discontinued 20 NA *Cohort 1: 1-month run-in of single-agent vemurafenib 960 mg BID followed by 4 infusions of ipilimumab 3 mg/kg every 3 weeks plus vemurafenib. Patient also had grade 2 increase in total bilirubin. Cohort 2: vemurafenib 760 mg BID plus ipilimumab 3 mg/kg every 3 wks. Patient also had grade 3 increase in total bilirubin. Ribas A, et al. N Engl J Med. 2013;368(14):
47 T-VEC: An HSV-1-Derived Oncolytic Immunotherapy Designed to Produce Local and Systemic Effects Local Effect: Virally-Induced Tumor Cell Lysis Selective viral replication in tumor tissue Tumor cells rupture for an oncolytic effect Systemic Effect: Tumor-Specific Immune Response Systemic tumorspecific immune response Death of distant cancer cells Kaufman HL, et al. J Clin Oncol. 2014;32(5S): Abstract 9008a.
48 T-VEC Responses in Injected And Uninjected Lesions Cycle 1 Cycle 13 Kaufman HL, et al. J Clin Oncol. 2014;32(5S): Abstract 9008a.
49 Primary Overall Survival 100% Events / N (%) Median (95% CI) in Months T-VEC 189 / 295 (64) 23.3 (19.5, 29.6) 80% GM-CSF 101 / 141 (72) 18.9 (16.0, 23.7) Kaplan-Meier Percent 60% 40% 20% Survival T-VEC GM-CSF Difference % (95% CI) 12 mo 73.7% 69.1% 4.6 (-4.7, 13.8) HR = 0.79 (95% CI: 0.62, 1.00) Unadjusted Log-rank P = mo 49.8% 40.3% 9.5 (-0.5, 19.6) 0% 36 mo 38.6% 30.1% 8.5 (-1.2, 18.1) 48 mo 32.6% 21.3% 11.3 (1.0, 21.5) Patients at risk: T-VEC GM-CSF Kaufman HL, et al. J Clin Oncol. 2014;32(5S): Abstract 9008a.
50 Percentage Change From Baseline Combination Ipilimumab and T-VEC in Melanoma * Only patients who received both T-Vec and ipilimumab. CR, CRu, and PD included. One patient with PD not shown in the plot because tumor burden could not be accurately calculated (missing post-baseline data) Percentage change from baseline: 538 Percentage change from baseline: 265 Stage IIIb (n = 1) Patients (N = 17) Stage IIIc (n = 3) Puzanov I, et al. J Clin Oncol. 2014;32(5s): Abstract Investigator-Assessed Responses, n (%) N = 18 * Overall response 10 (56) (95% CI: 31-79) Complete response 6 (33) Partial response 4 (22) Stable disease 3 (17) Progressive disease 5 (28) Stage IV M1a (n = 4) Stage IV M1b (n = 5) Stage IV M1c (n = 4)
51 Future Targets for Immunotherapy TIM-3 (T-cell immunoglobulin and mucin-domaincontaining molecule-3) Expressed by activated and exhausted T cells; natural ligand expressed on tumor cells Blockade of TIM-3 results in better immune function LAG-3: (lymphocyte activation gene-3) Expressed by activated T cells and Treg cells Blockade results in inhibition of Treg activity GITR (glucocorticoid-induced TNF-R related gene) Costimulatory molecule expressed on subsets of T cells Agonistic anti-gitr antibodies are in early clinical development
52 Other Immunomodulating Drugs in Development Anti-Ox40 Anti-CD27 Anti-CD40 Anti-CD137 (4-1BB)
53 Remaining Questions How do we select patients who will respond? How do we fit immunotherapy into the current treatment algorithm? Combination immunotherapy Sequencing with standard therapies How do we combine therapies to optimize the number of responding patients?
54
The Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationCANCER IMMUNOTHERAPY. Pocket Guide
CANCER IMMUNOTHERAPY Pocket Guide Unique Clinical Features Tumor Response Kinetics Response patterns associated with immune checkpoint blockade may differ from those associated with conventional therapies,
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationFuture Directions in Immunotherapy
Future Directions in Immunotherapy Naiyer Rizvi, MD Price Chair, Clinical Translational Medicine Director of Thoracic Oncology Director of Immuno-Oncology Columbia University Medical Center New York, New
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationAssessment of Efficacy and Immune Related RECIST criteria
Assessment of Efficacy and Immune Related RECIST criteria Dr Kenneth O Byrne Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia & Trinity College, Dublin, Ireland
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationBases biológicas de la moderna inmunoterapia en el tratamiento del cáncer
Bases biológicas de la moderna inmunoterapia en el tratamiento del cáncer Luis de la Cruz Merino. Sº Oncología Médica Hospital Universitario Virgen Macarena, Sevilla (lcruz-ibis@us.es) OUTLINE i. Definitions,
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationInmunoterapia en cáncer de pulmón. Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro
Inmunoterapia en cáncer de pulmón Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Current Therapeutic Landscape for NSCLC Current treatment strategies in NSCLC Various
More informationImproving Immunotherapy for Melanoma
Improving Immunotherapy for Melanoma David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/ Harvard Cancer Center Harvard Medical School Immunotherapy Improvement Model All patients All
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationInnovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationSlide 1. Slide 2. Slide 3. Immunotherapy in Lung Cancer. Disclosures. Objectives. No disclosures relevant to this talk
Slide 1 Immunotherapy in Lung Cancer Lyudmila Bazhenova, MD Associate Clinical Professor, Moores UCSD Cancer Center Slide 2 Disclosures No disclosures relevant to this talk Slide 3 Objectives Review immune
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationImmunotherapy in Lung Cancer. Lyudmila Bazhenova, MD Associate Clinical Professor, Moores UCSD Cancer Center
Immunotherapy in Lung Cancer Lyudmila Bazhenova, MD Associate Clinical Professor, Moores UCSD Cancer Center Disclosures No disclosures relevant to this talk Objectives Review immune pathways Immunology
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationImmunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Disclosures Madison Vaccines Inc co-founder, IP, consultant
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More information